Pomerantz LLP is investigating possible securities fraud claims related to Novartis AG following a significant stock price drop. Investors are urged to act.

Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."

An industry group warned that the UK risks missing out on significant cost savings from off-patent biosimilar medicines because of pricing structures and limited uptake within the National Health Service. This could affect drugmakers like Novartis that develop and supply biosimilar products for European markets.

Gini Dietrich runs Novartis's Super Bowl prostate cancer ad through the PESO Model® Diagnostic—and shows what happens when the ad has to be the whole system.

«Καλούμε τις Εισαγγελικές Αρχές να ορθώσουν ανάστημα», τονίζει ο Τομεάρχης Διαφάνειας του ΣΥΡΙΖΑ και βουλευτής Χανίων.

«Συλλάβετε και διώξτε τους επίορκους, όσο ψηλά κι αν βρίσκονται!»

Novartis shares slumped 11% in a single session this week, wiping nearly $30 billion off its market value and erasing all year-to-date gains after the late-stage clinical trial failure of the muscle-wasting disorder drug del-desiran, according to a Yahoo Finance report. The sharp sell-off has intens

Wer in den Aktienmarkt investiert und seine Rendite steigern will, kann auf Dividenden setzen. Börsen-Stars wie Roche, Nestlé der Novartis schütten jedes Jahr viel aus. Doch auch abseits der Schweizer Grosskonzerne finden Anleger attraktive Dividendenzahler.

Gini Dietrich runs Novartis's Super Bowl prostate cancer ad through the PESO Model® Diagnostic—and shows what happens when the ad has to be the whole system.

CAS, la división de información científica de la American Chemical Society, se asocia con Novartis para convertir décadas de reacciones químicas documentadas en datos listos para entrenar modelos de inteligencia artificial aplicados al descubrimiento de fármacos.

Fill in this form and get your report right now! Gain access to the onco / hem indications and the most popular mechanisms of action the leading BioPharma companies have been targeting and pursuing as at Q1 2025 (and beyond). In this concise report, we share the findings of the analysis of the portfolios and pipelines of 15 oncology and hematology companies and present a space overview and individual company profiles. Contact us at info@lqventures.com for more information or any other feedback. LucidQuest is committed to empowering its BioPharma and Life Sciences Investment industry stakeholders with up-to-date knowledge and analysis. Stay tuned for more free reports coming up in 2025 covering Cell and Gene Therapy, Multiple Sclerosis, Digital Health, Venture Capital investment in Pharma, and other spaces. The LucidQuest team

CAS has partnered with Novartis to improve AI-assisted reaction data accessibility, aiming to enhance drug discovery processes and research efficiency.

In a groundbreaking collaboration, CAS and Novartis aim to enhance reaction data accessibility to advance AI-enabled research, transforming the drug discovery landscape.